Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

WG, Wierda; TJ, Kipps; J, Mayer; S, Stilgenbauer; CD, Williams; A, Hellmann; T, Robak; RR, Furman; P, Hillmen; M, Trneny; MJ, Dyer; S, Padmanabhan; M, Piotrowska; T, Kozak; G, Chan; R, Davis; N, Losic; J, Wilms; CA, Russell; A, Osterborg

doi:10.1200/jco.2009.25.3187

Public

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Shared by NobleBlocks on Mar 1, 2010 • 12:00 AM UTC

Authors:

Wierda WG

Kipps TJ

Mayer J

Abstract

Purpose New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for alemtuzumab treatment; these groups have poor out...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!